(Q38539671)

English

Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designs

scientific article published on 29 June 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

1 reference

Europe PubMed Central

Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designs (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

author name string

Z Fadoukhair

1

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

D Zardavas

2

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

M A Chad

3

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

T Goulioti

4

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

P Aftimos

5

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

M Piccart

6

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

language of work or name

0 references

publication date

29 June 2015

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

35

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

1743-1749

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Trastuzumab--mechanism of action and use in clinical practice

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Personalized therapy for breast cancer: a dream or a reality?

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Repeated observation of breast tumor subtypes in independent gene expression data sets

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Breast cancer classification and prognosis based on gene expression profiles from a population-based study

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Luminal B breast cancer: molecular characterization, clinical management, and future perspectives

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Treatment of HER2-positive breast cancer: current status and future perspectives.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Triple-Negative Breast Cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Sequence analysis of mutations and translocations across breast cancer subtypes

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Comprehensive molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Mutant p53 in cancer: new functions and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

HER2 aberrations in cancer: implications for therapy

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Cancer genome landscapes

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Emerging targeted agents in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Genome remodelling in a basal-like breast cancer metastasis and xenograft

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

The AURORA initiative for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Should liver metastases of breast cancer be biopsied to improve treatment choice?

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Circulating tumour cells and cell-free DNA as tools for managing breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

A comparison of phase II study strategies

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Designing transformative clinical trials in the cancer genome era.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

The BATTLE trial: personalizing therapy for lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

N-of-1 double-blind, randomized controlled trial of tramadol to treat chronic cough

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

N of 1, two contemporary arm, randomised controlled clinical trial for bilateral epicondylitis: a new study design

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Single-patient (n-of-1) trials: a pragmatic clinical decision methodology for patient-centered comparative effectiveness research

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER).

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Molecular prescreening to select patient population in early clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

21 January 2018

Anticancer drug development: moving away from the old habits

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

31 March 2020

Beyond trastuzumab and lapatinib: new options for HER2-positive breast cancer .

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

31 March 2020

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

31 March 2020

Whole-genome analysis informs breast cancer response to aromatase inhibition

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

31 March 2020

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

31 March 2020

The landscape of cancer genes and mutational processes in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

31 March 2020

Clinical management of breast cancer heterogeneity

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

31 March 2020

Immunohistochemical study of estrogen receptors in primary breast carcinomas and their lymph node metastases including comparison of two monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

31 March 2020

HER2 status in a population-derived breast cancer cohort: discordances during tumor progression

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

31 March 2020

I-SPY 2 may change how clinical trials are conducted: researchers aim to accelerate approvals of cancer drugs

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

31 March 2020

Positive results for drug combo in I-SPY 2 trial

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

31 March 2020

Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26119941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Drug combo shows promise in NRAS-mutant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.249

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/ONC.2015.249

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38539671&oldid=2201805998"